Clinical trial · Observational
Metabolomics and Transcriptomics of Low- and High-Grade Gliomas
Metabolomica e Trascrittomica Dei Gliomi a Basso ed Alto Grado (GlioMeTra) L2093
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The goal of this observational study is to better define the molecular profile of rare brain tumors (gliomas) based on the levels of their metabolites and transcripts (the intermediate step between DNA information and proteins). The main question it aims to answer is to identify new brain tumour subgroups of clinical relevance that might explain the very different history these patients might follow. Additionally, studies on gliomas require cellular cultures and animal models for the development of new medications, but these models are still scarce and rudimental for many types of gliomas. The second aim of this study is to implement better models for these tumors, for a more effective development of new medications. Patients enrolled in this study will not undergo any additional procedures with respect to those necessary for gold-standard management of these brain tumors. A small sample of the resected tumour will be used for advanced analyses investigating the metabolic and transcriptomic profile and used for temptative establishment of cellular cultures and animal models of these pathologies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| IDH Mutant Lower-Grade Gliomas | — | UNRESOLVED | — |
| IDH Wildtype Glioblastoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Brain tumour patients
- description
- IDHwt GBMs and IDHmutant LGGs
Primary outcomes (2)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- (up to 180 months)
- description
- time from surgery to evidence of radiological progression at MRI
- measure
- Overall Survival (OS)
- timeFrame
- (up to 180 months)
- description
- Time from surgery to tumor-related death
Secondary outcomes (2)
- measure
- Histological-molecular diagnosis (integration of immunohistochemistry and molecular evaluation of IDH1/2, ATRX and 1p/19q chromosomal deletion, EGFR mutation/amplification, TERT promoter mutation, chromosomal aberration +7/-10)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects who sign the informed consent form for study participation * Males and females * Age ≥ 18 years * Patients with a radiological diagnosis of central nervous system enlargement on routine preoperative clinical imaging (MRI/PET) who will attend the OU outpatient clinics or the OGSA Emergency Department and are candidates for surgery * Availability of medical history. Exclusion Criteria: * Age \< 18 years * Subjects unable to understand and freely provide consent to the study * Current pregnancy and/or breastfeeding (self-declaration).
References
Publications (0)
Data not yet available